 Liping Yu
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Autoantibodies | 54 | 2023 | 1468 | 5.690 |
Why?
| | Diabetes Mellitus, Type 1 | 58 | 2023 | 3630 | 3.870 |
Why?
| | Luminescent Measurements | 7 | 2021 | 76 | 3.020 |
Why?
| | Celiac Disease | 8 | 2023 | 286 | 2.360 |
Why?
| | Islets of Langerhans | 22 | 2023 | 791 | 2.090 |
Why?
| | Glutamate Decarboxylase | 15 | 2022 | 166 | 1.960 |
Why?
| | Electrochemical Techniques | 4 | 2021 | 48 | 1.780 |
Why?
| | High-Throughput Screening Assays | 3 | 2020 | 139 | 1.650 |
Why?
| | Autoimmune Diseases | 5 | 2020 | 428 | 1.420 |
Why?
| | Zinc Transporter 8 | 10 | 2021 | 87 | 1.400 |
Why?
| | Mass Screening | 11 | 2021 | 1192 | 1.320 |
Why?
| | Transglutaminases | 6 | 2023 | 153 | 1.290 |
Why?
| | Insulin Antibodies | 10 | 2016 | 105 | 1.220 |
Why?
| | Prediabetic State | 6 | 2015 | 244 | 1.150 |
Why?
| | Cation Transport Proteins | 8 | 2013 | 131 | 1.110 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 6 | 2016 | 63 | 0.990 |
Why?
| | Insulin | 20 | 2021 | 2330 | 0.960 |
Why?
| | Proinsulin | 4 | 2016 | 52 | 0.920 |
Why?
| | Sensitivity and Specificity | 14 | 2022 | 1847 | 0.920 |
Why?
| | Diagnostic Techniques, Endocrine | 3 | 2019 | 14 | 0.690 |
Why?
| | Autoantigens | 7 | 2021 | 420 | 0.670 |
Why?
| | Antibodies, Viral | 2 | 2023 | 602 | 0.570 |
Why?
| | Autoimmunity | 12 | 2023 | 863 | 0.550 |
Why?
| | Child, Preschool | 25 | 2023 | 10522 | 0.500 |
Why?
| | Child | 32 | 2023 | 20962 | 0.460 |
Why?
| | Biomarkers | 7 | 2022 | 3971 | 0.440 |
Why?
| | Infant | 19 | 2023 | 9018 | 0.420 |
Why?
| | Glucose Intolerance | 1 | 2015 | 142 | 0.420 |
Why?
| | Adolescent | 28 | 2023 | 20451 | 0.410 |
Why?
| | Humans | 62 | 2023 | 129847 | 0.400 |
Why?
| | Luminescence | 4 | 2016 | 37 | 0.380 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 86 | 0.360 |
Why?
| | Peptide Fragments | 8 | 2016 | 695 | 0.320 |
Why?
| | Male | 29 | 2021 | 63759 | 0.320 |
Why?
| | Immunologic Factors | 1 | 2011 | 229 | 0.310 |
Why?
| | Female | 33 | 2021 | 68829 | 0.310 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2444 | 0.310 |
Why?
| | Quality Improvement | 1 | 2017 | 1112 | 0.310 |
Why?
| | Young Adult | 13 | 2021 | 12467 | 0.310 |
Why?
| | Protein Precursors | 3 | 2021 | 128 | 0.310 |
Why?
| | Radioimmunoassay | 4 | 2016 | 175 | 0.300 |
Why?
| | Radioligand Assay | 2 | 2009 | 48 | 0.290 |
Why?
| | Adult | 17 | 2023 | 35634 | 0.280 |
Why?
| | Antibodies, Antinuclear | 1 | 2007 | 66 | 0.270 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2007 | 43 | 0.270 |
Why?
| | Risk Factors | 10 | 2021 | 9801 | 0.260 |
Why?
| | Disease Progression | 9 | 2019 | 2628 | 0.250 |
Why?
| | Seroepidemiologic Studies | 3 | 2023 | 157 | 0.240 |
Why?
| | Insulin-Secreting Cells | 3 | 2019 | 367 | 0.240 |
Why?
| | Addison Disease | 3 | 2012 | 43 | 0.230 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2007 | 247 | 0.220 |
Why?
| | Middle Aged | 11 | 2021 | 31177 | 0.220 |
Why?
| | CD4-Positive T-Lymphocytes | 4 | 2021 | 1058 | 0.220 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2011 | 836 | 0.210 |
Why?
| | Case-Control Studies | 3 | 2021 | 3384 | 0.210 |
Why?
| | Isoenzymes | 2 | 2004 | 301 | 0.190 |
Why?
| | Disease Susceptibility | 2 | 2020 | 334 | 0.190 |
Why?
| | Electrochemistry | 1 | 2021 | 79 | 0.190 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 254 | 0.180 |
Why?
| | China | 1 | 2021 | 192 | 0.180 |
Why?
| | Predictive Value of Tests | 6 | 2015 | 1951 | 0.180 |
Why?
| | Genotype | 9 | 2016 | 1829 | 0.180 |
Why?
| | Polymorphism, Genetic | 4 | 2017 | 636 | 0.170 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 158 | 0.170 |
Why?
| | DNA | 1 | 2007 | 1406 | 0.170 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4896 | 0.170 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 106 | 0.160 |
Why?
| | Steroid 21-Hydroxylase | 3 | 2012 | 30 | 0.160 |
Why?
| | Health Fairs | 1 | 2019 | 9 | 0.160 |
Why?
| | Risk Assessment | 3 | 2020 | 3269 | 0.160 |
Why?
| | Prognosis | 5 | 2021 | 3773 | 0.150 |
Why?
| | Colorado | 4 | 2023 | 4410 | 0.150 |
Why?
| | Prevalence | 3 | 2023 | 2564 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2021 | 333 | 0.150 |
Why?
| | Epitopes | 4 | 2021 | 474 | 0.140 |
Why?
| | Cohort Studies | 3 | 2021 | 5444 | 0.140 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.140 |
Why?
| | Antibody Specificity | 4 | 2011 | 185 | 0.140 |
Why?
| | Population Surveillance | 1 | 2020 | 439 | 0.140 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 707 | 0.140 |
Why?
| | Health Care Costs | 1 | 2020 | 367 | 0.130 |
Why?
| | Mice, Inbred NOD | 8 | 2008 | 587 | 0.130 |
Why?
| | Disease Management | 1 | 2020 | 592 | 0.130 |
Why?
| | T-Lymphocytes | 5 | 2023 | 1937 | 0.130 |
Why?
| | HLA-DQ Antigens | 5 | 2016 | 179 | 0.120 |
Why?
| | Risk | 2 | 2019 | 860 | 0.120 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 577 | 0.120 |
Why?
| | Incidence | 1 | 2021 | 2646 | 0.120 |
Why?
| | Aged | 5 | 2021 | 22107 | 0.120 |
Why?
| | Transcription Factors | 2 | 2017 | 1645 | 0.110 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2004 | 165 | 0.110 |
Why?
| | Poly I-C | 2 | 2004 | 62 | 0.100 |
Why?
| | Biopsy | 1 | 2016 | 1089 | 0.100 |
Why?
| | Prospective Studies | 6 | 2023 | 7158 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3089 | 0.100 |
Why?
| | Histocompatibility Antigens Class I | 3 | 2009 | 200 | 0.100 |
Why?
| | HLA-DR Antigens | 4 | 2016 | 223 | 0.090 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 143 | 0.090 |
Why?
| | Pedigree | 3 | 2017 | 483 | 0.090 |
Why?
| | Glucose Tolerance Test | 1 | 2012 | 355 | 0.090 |
Why?
| | Rituximab | 1 | 2011 | 164 | 0.090 |
Why?
| | HLA-DR4 Antigen | 3 | 2011 | 78 | 0.080 |
Why?
| | HLA-DR3 Antigen | 3 | 2011 | 80 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 766 | 0.080 |
Why?
| | Mice | 14 | 2008 | 16983 | 0.070 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2724 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 109 | 0.070 |
Why?
| | Age of Onset | 3 | 2019 | 494 | 0.070 |
Why?
| | Family | 1 | 2012 | 646 | 0.070 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2007 | 6 | 0.070 |
Why?
| | Peptides | 2 | 2023 | 926 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1434 | 0.070 |
Why?
| | Interferon-alpha | 2 | 2009 | 194 | 0.070 |
Why?
| | Antibody Formation | 1 | 2008 | 291 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 107 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 650 | 0.070 |
Why?
| | Double-Blind Method | 1 | 2011 | 1877 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2004 | 1119 | 0.070 |
Why?
| | CD4 Antigens | 2 | 2003 | 137 | 0.060 |
Why?
| | Animals | 15 | 2008 | 35409 | 0.060 |
Why?
| | C-Peptide | 2 | 2016 | 163 | 0.060 |
Why?
| | Anaphylaxis | 2 | 2004 | 99 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 14 | 0.060 |
Why?
| | Models, Biological | 1 | 2011 | 1724 | 0.060 |
Why?
| | Twins, Dizygotic | 1 | 2004 | 181 | 0.050 |
Why?
| | Endocrine System Diseases | 1 | 2004 | 33 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 94 | 0.050 |
Why?
| | Siblings | 1 | 2004 | 216 | 0.050 |
Why?
| | Mice, Inbred BALB C | 5 | 2004 | 1248 | 0.050 |
Why?
| | Glycolipids | 1 | 2004 | 42 | 0.050 |
Why?
| | Remission Induction | 1 | 2004 | 274 | 0.050 |
Why?
| | Immunoglobulin E | 2 | 2021 | 330 | 0.050 |
Why?
| | Genetic Testing | 1 | 2005 | 422 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 34 | 0.050 |
Why?
| | Fetal Blood | 1 | 2004 | 318 | 0.050 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 17 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Seroconversion | 1 | 2021 | 46 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | Canada | 1 | 2002 | 353 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 52 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2002 | 287 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2008 | 2062 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2002 | 183 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 84 | 0.040 |
Why?
| | Immunoglobulin G | 2 | 2021 | 851 | 0.040 |
Why?
| | Infant, Newborn | 4 | 2005 | 5772 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 106 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 35 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 276 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 201 | 0.040 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 201 | 0.040 |
Why?
| | Age Factors | 2 | 2004 | 3161 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 233 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 228 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 1199 | 0.040 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2012 | 133 | 0.040 |
Why?
| | Tissue Donors | 1 | 2021 | 391 | 0.040 |
Why?
| | Alleles | 3 | 2009 | 843 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 38 | 0.040 |
Why?
| | Cell Death | 1 | 2019 | 353 | 0.040 |
Why?
| | Community Health Services | 1 | 2019 | 229 | 0.030 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 197 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 569 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2002 | 1005 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5085 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1368 | 0.030 |
Why?
| | Mice, Transgenic | 3 | 2008 | 2135 | 0.030 |
Why?
| | Phenotype | 2 | 2021 | 3062 | 0.030 |
Why?
| | Hydrocortisone | 2 | 2012 | 306 | 0.030 |
Why?
| | Time Factors | 3 | 2016 | 6550 | 0.030 |
Why?
| | HLA-DQ beta-Chains | 2 | 2009 | 61 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 254 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 59 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 756 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1033 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 295 | 0.030 |
Why?
| | Proteomics | 1 | 2022 | 1058 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1326 | 0.030 |
Why?
| | Blood Glucose | 3 | 2016 | 2103 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 697 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2004 | 146 | 0.030 |
Why?
| | Adoptive Transfer | 2 | 2005 | 218 | 0.030 |
Why?
| | Mice, SCID | 2 | 2005 | 350 | 0.030 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2004 | 47 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1501 | 0.020 |
Why?
| | Spleen | 2 | 2005 | 508 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 787 | 0.020 |
Why?
| | Renin | 1 | 2012 | 32 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2015 | 870 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1221 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 36 | 0.020 |
Why?
| | Immunization | 2 | 2004 | 411 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 34 | 0.020 |
Why?
| | Homozygote | 1 | 2009 | 195 | 0.020 |
Why?
| | HLA-DRB1 Chains | 1 | 2009 | 108 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2009 | 163 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 177 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2011 | 773 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2005 | 2888 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 1074 | 0.020 |
Why?
| | ROC Curve | 1 | 2009 | 504 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 177 | 0.020 |
Why?
| | Age Distribution | 1 | 2007 | 372 | 0.020 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 28 | 0.010 |
Why?
| | Rats | 2 | 2004 | 5487 | 0.010 |
Why?
| | Thyroglobulin | 1 | 2005 | 27 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 23 | 0.010 |
Why?
| | United States | 1 | 2002 | 13913 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 2004 | 121 | 0.010 |
Why?
| | Family Health | 1 | 2005 | 198 | 0.010 |
Why?
| | B7-1 Antigen | 1 | 2004 | 55 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 114 | 0.010 |
Why?
| | Endocrine System | 1 | 2004 | 20 | 0.010 |
Why?
| | Disease Models, Animal | 2 | 2004 | 4077 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 271 | 0.010 |
Why?
| | HLA Antigens | 1 | 2005 | 235 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 2003 | 234 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 96 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 568 | 0.010 |
Why?
| | Delivery, Obstetric | 1 | 2004 | 136 | 0.010 |
Why?
| | Enkephalins | 1 | 2002 | 16 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2004 | 5468 | 0.010 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 25 | 0.010 |
Why?
| | Reference Values | 1 | 2004 | 796 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 75 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 53 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 487 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 96 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1686 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1724 | 0.010 |
Why?
| | Antibodies | 1 | 2003 | 399 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 105 | 0.010 |
Why?
| | Regression Analysis | 1 | 2004 | 998 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 229 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4102 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1271 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2002 | 363 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 2057 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2271 | 0.010 |
Why?
| | Proteins | 1 | 2004 | 944 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 804 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1690 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1348 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 6423 | 0.010 |
Why?
|
|
Yu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|